CSF markers for incipient Alzheimer's disease (Q35541472)

8 August 2017

1 reference

title

CSF markers for incipient Alzheimer's disease (English)

1 reference

8 August 2017

0 references

Harald Hampel

1 reference

8 August 2017

Kaj Blennow

1 reference

8 August 2017

publication date

1 October 2003

1 reference

8 August 2017

1 reference

8 August 2017

1 reference

8 August 2017

1 reference

8 August 2017

page(s)

605-613

1 reference

Mild cognitive impairment: clinical characterization and outcome

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Clinical-neuropathological correlations in Alzheimer's disease and related dementias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Diagnostic accuracy of Alzheimer's disease: a clinicopathological study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

A critical discussion of the role of neuroimaging in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

One-carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Amyloid plaque core protein in Alzheimer disease and Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Low cerebrospinal-fluid concentrations of soluble amyloid beta-protein precursor in hereditary Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Both total and phosphorylated tau are increased in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Cerebrospinal protein tau is elevated in early Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Increased cerebrospinal fluid cAMP levels in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Diagnostic accuracy of Alzheimer's disease: a neuropathological study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

1 reference

7 January 2021

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Research evaluation and prospective diagnosis of dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Long-term follow-up of patients who received 10,098 spinal anesthetics; syndrome of decreased intracranial pressure (headache and ocular and auditory difficulties).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900530-1

7 January 2021

10.1016/S1474-4422(03)00530-1

Identifiers

DOI

1 reference

8 August 2017

1 reference